Allenex agrees to sell holding in AnaMar

Allenex has agreed to sell its holding in AnaMar AB to the company’s main owner
Koncentra Holding. The price is set to 1,7 mkr. Allenex became an owner in
AnaMar 1998. Their focus area is chronic joint diseases. Allenex has not
participated in the financing of AnaMar in recent years and the equity that now
is being sold equal about 2,1 % of the total share capital in AnaMar. The
Allenex book value of this equity is zero. The deal will therefore mean
corresponding revenue for Allenex in the second quarter of 2013. The sale will
be finished in June.

”By selling our remaining holding in AnaMar, we have now divested all holdings
in life science research companies. The transformation of Allenex into an
operational company within transplantation diagnostics is thereby fully
implemented”, says Allenex CEO Anders Karlsson in a comment.

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on June 03, 2013, at 08.40 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the
Allenex group.